Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial

Author(s): Marc-Andrea Baertsch1,2; Jana Schlenzka1; Thomas Hielscher3; Marc S. Raab1,2,4; Sandra Sauer1; Maximilian Merz5; Elias Karl Mai1; Carsten Müller-Tidow1,4; Steffen Luntz6; Anna Jauch7; Peter Brossart8; Martin Goerner9; Stefan Klein10; Bertram Glass11; Peter Reimer12; Ullrich Graeven13; Roland Fenk14; Mathias Haenel15; Ivana von Metzler16; Hans W. Lindemann17; Christof Scheid18; Igor-Wolfgang Blau19; Hans J. Salwender20; Richard Noppeney21; Britta Besemer22; Katja C. Weisel23; Hartmut Goldschmidt1,4
Source: Blood (2025) 145 (16): 1780–1787.

Dr. Maen Hussein's Thoughts

Is the need to transplant declining? Salvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM. Patients who relapsed were treated with high-dose chemotherapy followed by maintenance lenalidomide vs dexamethasone and lenalidomide and progression-free survival (PFS) was 20 vs 19 months.

ABSTRACT

The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2

Author Affiliations

1Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany;2Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany;3Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;4National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;5Department of Hematology, Cell Therapy, Hemostaseology and Infectiology, Leipzig University Hospital, Leipzig, Germany;6Coordination Centre for Clinical Trials, University Hospital Heidelberg, Heidelberg, Germany;7Institute for Human Genetics, University of Heidelberg, Heidelberg, Germany;8Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, Medizinische Klinik und Poliklinik III, University Hospital Bonn, Bonn, Germany;9Department of Hematology, Oncology and Palliative Care, Community Hospital Bielefeld, Bielefeld, Germany;10Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany;11Department of Hematology and Cellular Therapy, Helios Hospital Berlin-Buch, Berlin, Germany;12Department of Hematology, Oncology and Stem Cell Transplantation, Evangelische Kliniken Essen-Mitte, Essen, Germany;13Department of Hematology, Oncology and Gastroenterology, Kliniken Maria Hilf GmbH, Mönchengladbach, Germany;14Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany;15Department of Hematology, Oncology and Stem Cell Transplantation, Klinikum Chemnitz GmbH, Chemnitz, Germany;16Department of Hematology and Oncology, Goethe University, Frankfurt, Germany;17Department of Hematology and Oncology, Katholisches Krankenhaus Hagen gem. GmbH, Hagen, Germany;18Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany;19Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany;20Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany;21Department of Hematology, University Hospital Essen, Essen, Germany;22Department of Hematology, Oncology, Immunology, and Rheumatology, University of Tuebingen, Tuebingen, Germany;23Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles